R&D News | pharmaphorum

News

Bayer reveals phase 3 data for improved MRI contrast agent

Bayer is close to filing a new MRI contrast agent that can reduce levels of gadolinium, which can have health and environmental consequences.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

News

Black and white image of a child holding a conch to their ear

Evidence builds behind Regeneron's deafness gene therapy

Ten out of 11 children with congenital deafness treated with a gene therapy developed by Regeneron have seen "notable" improvements in hearing.

News

Ex-CDER chief Cavazzoni rejoins Pfizer as CMO

In a move that will raise eyebrows in Washington, Pfizer has hired former FDA director Patricia Cavazzoni as its new chief medical officer.

News

Troubled gene therapy player bluebird sold for a song

At risk of defaulting on financial commitments, gene therapy firm bluebird bio has agreed to sell itself to private equity firms at a knockdown price.

News

Trial of Boehringer's cystic fibrosis gene therapy imminent

Boehringer's cystic fibrosis gene therapy is poised to start clinical testing, hoping to offer a one-shot alternative to costly CFTR modulator drugs.

Bayer reveals phase 3 data for improved MRI contrast agent

Data cues up AZ oral SERD filing in first-line breast cancer

Evidence builds behind Regeneron's deafness gene therapy

Ex-CDER chief Cavazzoni rejoins Pfizer as CMO

Troubled gene therapy player bluebird sold for a song

Trial of Boehringer's cystic fibrosis gene therapy imminent

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks